Immunotherapy is one of the most encouraging treatment for cancer patients, and the most common immunotherapy strategy includes the interruption of the interaction between immune checkpoints expressed on tumor and immune cells, especially targeting PD-L1/PD-1 (25). Here, PDCD1 is linked to cancer.